Sommaire

• • ·Looking beyond the headlines

    Page :561

     
• • ·Building capacity for cancer control in developing countries: the need for a paradigm shift

    Page :562-563

    Ian Magrath

     
• • ·Radium-223 for men with hormone-refractory prostate cancer and bone metastases

    Page :564-565

    Mike D Shelley, Malcolm D Mason

    
• • ·Trabectedin—a targeted chemotherapy?

    Page :565-567

    Margaret von Mehren

    
• • ·Use of antidepressants for depression in patients with advanced cancer

    Page :567-568

    Michael Fisch

    
• • ·At last—progress in the assessment of the adverse effects of cancer treatments

    Page :568-570

    Jean-Claude Horiot

    
• • ·Considerations and restrictions for non-operative treatment of rectal cancer in selected patients

    Page :570-571

    Marcel den Dulk, Cornelis JH van de Velde

    
• • ·Current TNM staging of colorectal cancer

    Page :572-573

    Frederick L Greene

    
• • ·Palliative care: for whom and by whom?

    Page :573-574

    An KL Reyners, Frans T Peters, Cees A van Minnen

    
• • ·Breast cancer: a call for papers

    Page :574

    David Collingridge

    
• • ·Erratum

    Page :574

    David Collingridge

    
• • ·Dentists: a crucial part to play in oral cancer

    Page :575

    Claire Tilstone

     
• • ·PSA spikes not always cause for alarm

    Page :576

    Cathel Kerr

     
• • ·Trastuzumab for advanced bladder cancer

    Page :576

    Nayanah Siva

    
• • ·Death threats for discrepancies over treatment data

    Page :577

    Adrian Burton

    
• • ·Capecitabine and irinotecan in advanced gastric cancer

    Page :577

    Sharan Prakash Sharma

     
• • ·Electrical killing fields for cancer cells

    Page :578

    Kathryn Senior

     
• • ·Docetaxel for prostate cancer

    Page :578

    Marta Paterlini

    
• • ·Neoadjuvant combination for stage II–III breast cancer

    Page :579

    Sanjit Bagchi

    
• • ·Tyrosine kinase inhibitors: who will benefit?

    Page :579

    Jane Bradbury

     
• • ·2007 Joint Annual Meeting of the World Conference on Interventional Oncology and the Society for Thermal Medicine, Washington, DC, USA; May 14–17, 2007

    Page :580

    Lidia Siemaszkiewicz

    Plan Plan  
• • ·43rd Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, USA; June 1–5, 2007

    Page :581

    Sally Simpson

    Plan Plan
• • ·10th Congress of the European Association of Palliative Care, Budapest, Hungary; June 7–9, 2007

    Page :582

    David Collingridge

    Plan Plan  
• • ·Breast cancer: an artistic view

    Page :583-585

    Jayant S Vaidya

     
• • ·Alice in Cancerland

    Page :585-586

    Talha Burki

     
• • ·Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study

    Page :587-594

    Sten Nilsson, Lars Franzén, Christopher Parker, Christopher Tyrrell, René Blom, Jan Tennvall, Bo Lennernäs, Ulf Petersson, Dag C Johannessen, Michael Sokal, Katharine Pigott, Jeffrey Yachnin, Michael Garkavij, Peter Strang, Johan Harmenberg, Bjørg Bolstad, Øyvind S Bruland

    Résumé Résumé Plan Plan  
• • ·Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study

    Page :595-602

    Federica Grosso, Robin L Jones, George D Demetri, Ian R Judson, Jean-Yves Blay, Axel Le Cesne, Roberta Sanfilippo, Paola Casieri, Paola Collini, Palma Dileo, Carlo Spreafico, Silvia Stacchiotti, Elena Tamborini, Juan Carlos Tercero, Josè Jimeno, Maurizio D’Incalci, Alessandro Gronchi, Jonathan A Fletcher, Silvana Pilotti, Paolo G Casali

    Résumé Résumé Plan Plan   
• • ·Effect of sertraline on symptoms and survival in patients with advanced cancer, but without major depression: a placebo-controlled double-blind randomised trial

    Page :603-612

    Martin R Stockler, Rachel O’Connell, Anna K Nowak, David Goldstein, Jane Turner, Nicholas RC Wilcken, David Wyld, Ehtesham A Abdi, Amanda Glasgow, Philip J Beale, Michael Jefford, Haryana Dhillon, Stephane Heritier, Candace Carter, Ian B Hickie, R John Simes, on behalf of the Zoloft’s Effects on Symptoms and survival Time (ZEST) Trial Group

    Résumé Résumé Plan Plan   
• • ·TAME: development of a new method for summarising adverse events of cancer treatment by the Radiation Therapy Oncology Group

    Page :613-624

    Andy Trotti, Thomas F Pajak, Clement K Gwede, Rebecca Paulus, Jay Cooper, Arlene Forastiere, John A Ridge, Deborah Watkins-Bruner, Adam S Garden, K Kian Ang, Wally Curran

    Résumé Résumé Plan Plan  
• • ·Non-operative treatment after neoadjuvant chemoradiotherapy for rectal cancer

    Page :625-633

    Brian DP O’Neill, Gina Brown, RJ Heald, David Cunningham, Diana M Tait

    Résumé Résumé Plan Plan  
• • ·Gemcitabine-associated thrombotic thrombocytopenic purpura

    Page :634-641

    Melanie Zupancic, Prabodh C Shah, Farheen Shah-Khan, S Nagendra

    Résumé Résumé Plan Plan  
• • ·Gestational trophoblastic neoplasia—pathogenesis and potential therapeutic targets

    Page :642-650

    Ie-Ming Shih

    Résumé Résumé Plan Plan  
• • ·The future of the TNM staging system in colorectal cancer: time for a debate?

    Page :651-657

    Philip Quirke, Geraint T Williams, Nadine Ectors, Arzu Ensari, Françoise Piard, Iris Nagtegaal

    Résumé Résumé Plan Plan  
• • ·JAK2-V617F mutation in a patient with Philadelphia-chromosome-positive chronic myeloid leukaemia

    Page :658-660

    Alwin Krämer, Andreas Reiter, Jens Kruth, Philipp Erben, Andreas Hochhaus, Martin Müller, Nicholas CP Cross, Amy V Jones, Anthony D Ho, Manfred Hensel